HC Wainwright Expects Weaker Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research note issued to investors on Wednesday, September 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.40) for the quarter, down from their prior forecast of ($0.38). HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q4 2026 earnings at $0.13 EPS, FY2026 earnings at ($1.88) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at $0.19 EPS, Q3 2027 earnings at $0.49 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.31 EPS.

Several other research analysts also recently issued reports on BBIO. Canaccord Genuity Group upped their price target on shares of BridgeBio Pharma from $104.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Bank of America raised their price objective on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $110.00 target price on shares of BridgeBio Pharma in a research note on Tuesday, August 11th. Citigroup upped their target price on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Finally, UBS Group reissued a “buy” rating on shares of BridgeBio Pharma in a research note on Wednesday. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.53.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $75.41 on Friday. BridgeBio Pharma has a twelve month low of $48.78 and a twelve month high of $93.42. The firm has a market cap of $14.74 billion, a PE ratio of -21.12 and a beta of 0.97. The business has a fifty day moving average of $80.65 and a 200-day moving average of $73.61.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The business had revenue of $243.68 million during the quarter, compared to the consensus estimate of $220.91 million. The business’s quarterly revenue was up 120.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.95) earnings per share.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently bought and sold shares of BBIO. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma during the 1st quarter worth $35,000. First Trust Advisors LP boosted its position in shares of BridgeBio Pharma by 200.4% in the 2nd quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock worth $11,386,000 after purchasing an additional 175,918 shares during the last quarter. Baird Financial Group Inc. boosted its position in shares of BridgeBio Pharma by 1.8% in the 2nd quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock worth $1,816,000 after purchasing an additional 731 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of BridgeBio Pharma during the second quarter worth $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of BridgeBio Pharma by 2.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after purchasing an additional 2,206 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Hannah Valantine sold 2,196 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total transaction of $150,579.72. Following the completion of the sale, the director directly owned 9,259 shares of the company’s stock, valued at approximately $634,889.63. The trade was a 19.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer Cook sold 148,589 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the transaction, the director owned 8,383 shares in the company, valued at approximately $742,230.82. The trade was a 94.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 347,343 shares of company stock valued at $27,591,000. 14.23% of the stock is currently owned by insiders.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target. Barclays and Cantor Fitzgerald also maintained Buy ratings, supporting the bullish view that BridgeBio’s pipeline could drive substantial long-term value. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma Barclays Sticks to Its Buy Rating for BridgeBio Pharma
• Positive Sentiment: BridgeBio will present new PROPEL 3 data on oral infigratinib’s impact on medical complications in children with achondroplasia at the ESPE 2026 meeting on September 9. Additional presentations will cover longer-term efficacy and safety, infant and toddler studies, and hypochondroplasia. The data could provide an important catalyst for the company’s skeletal-dysplasia program. BridgeBio to Present New Data on Oral Infigratinib
• Neutral Sentiment: The upcoming infigratinib presentations are potentially significant, but the announcement did not include the actual clinical results. Because the drug remains investigational, investors will likely wait for the September 9 data before assigning greater value to the program.
• Negative Sentiment: HC Wainwright lowered EPS estimates across nearly every reported period: Q3 2026 to a loss of $0.40 from $0.38, FY2026 to a loss of $1.88 from $1.50, Q1 2027 to a loss of $0.18 from $0.11, and FY2027 to $1.31 from $2.19. Estimates for Q2, Q3 and Q4 2027 were also reduced. The cuts suggest a slower earnings ramp and are likely the main reason the news is pressuring BBIO, despite the unchanged Buy rating and $120 target.
• Negative Sentiment: BridgeBio remains expected to report a full-year loss of approximately $2.60 per share, reinforcing concerns about near-term profitability. Reported insider activity also shows extensive selling and no purchases during the past six months, which may add to investor caution.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.